Lexeo Therapeutics (Lexeo Therapeutics) Interest Expense : $-0.19 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Lexeo Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Lexeo Therapeutics's interest expense for the three months ended in Mar. 2024 was $ -0.04 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.19 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Lexeo Therapeutics's Operating Income for the three months ended in Mar. 2024 was $ -23.29 Mil. Lexeo Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $ -0.04 Mil. Lexeo Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lexeo Therapeutics Interest Expense Historical Data

The historical data trend for Lexeo Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexeo Therapeutics Interest Expense Chart

Lexeo Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Interest Expense

-0.15

-0.09

-0.21

Lexeo Therapeutics Quarterly Data
	Dec20	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial					-0.05	-0.05	-0.05	-0.05	-0.04

Lexeo Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.19 Mil.

Lexeo Therapeutics (NAS:LXEO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lexeo Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $-0.04 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-23.29 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $8.63 Mil.

Lexeo Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Lexeo Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Lexeo Therapeutics (Lexeo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexeo Therapeutics Inc (NAS:LXEO) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

345 Park Avenue South, Floor 6, New York, NY, USA, 10010

Website

https://www.lexeotx.com

Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.

Executives

Lundbeckfond Invest A/s	10 percent owner	SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100
Longitude Capital Partners Iv, Llc	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Omega Fund Vi Gp, L.p.	10 percent owner	888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Omega Fund Vi, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Richard Nolan Townsend	director, officer: Chief Executive Officer	C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Jenny Robertson	officer: Chief Legal and Admin. Officer	C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Paul Mccormac	officer: Chief Technical Officer	C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Bernard Davitian	director	C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Eric Adler	officer: Chief Scientific Officer	C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010
Brenda Cooperstone	director	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Longitude Venture Partners Iv, L.p.	10 percent owner	2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Omega Fund Vi Gp Manager, Ltd.	10 percent owner	888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Paula H Cholmondeley	director	221 W PHILADELPHIA ST, SUITE 60W, YORK PA 17401-2991
Reinaldo M Diaz	director	C/O DIAZ & ALTSCHUL CAPITAL, 950 THIRD AVE, NEW YORK NY 10022
Mette Kirstine Agger	director	C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830

Lexeo Therapeutics (Lexeo Therapeutics) Headlines

From GuruFocus

Lexeo Therapeutics Inc (LXEO) Reports Q3 2023 Financial Results and Advances Clinical Programs

By GuruFocus Research • 12-13-2023